Salubris pharma

Salubris refiles for Hong Kong IPO

Salubris refiles for Hong Kong IPO as generics lose steam

The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…
002294.SHE

Recent Articles

RELATED ARTICLES

  1. CSPC Innovation IPO
    CSPC Innovation pursues Hong Kong IPO as parent profits shrink
    300765.SHE
  2. BRIEF: Capital Securities gets regulatory nod, refiles for Hong Kong IPO
    601136.SHG
  3. Drug setback leaves Ascletis with an all-in bet on weight loss
    1672.HK
  4. Jacobio Pharma poised to turn a profit from precision cancer drugs
  5. Drug spin-off trend gains traction with IPO by Hengrui offshoot
    1276.HK
    600276.SHG
  6. Precision-drug maker Impact Therapeutics ignites IPO frenzy
  7. Alebund soars in Hong Kong debut on kidney treatment hopes 
    9637.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva